Loading...
Office
Journal

Table of Content

31 July 2021, Volume 18 Issue 4
   Next Issue
Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) in the Treatment of Type 2 Diabetes Mellitus #br#
ZHANG Kaiyue, WU Tijun
2021, 18(4):  321-324. 
Abstract ( 121 )   PDF (2188KB) ( 0 )  
Related Articles | Metrics
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized byhyperglycemia and hyperlipidemia. Persistent elevated blood glucose and lipids cause complications in various important organs and tissues, which seriously threaten human life and health. Therefore, the prevention and treatment of T2DM has become a huge challenge faced by pharmaceutical research and development workers. Glucagon-like peptide-1 (GLP-1) is a brain-gut peptide secreted by endocrine cells in the ileum. Its receptor is currently used as a target for anti-T2DM drugs. GLP-1 receptor agonists (GLP-1RA) have been a hotspot in research and development institutions such as pharmaceutical companies in recent years, and have been proven to play an active and effective role in the treatment of T2DM. This article summarizes the research progress of GLP-1RA in recent years.